Stifel maintains Buy on Bicara stock with $47 target
Stifel analysts reiterated a Buy rating on Bicara Therapeutics Inc (NASDAQ:BCAX), maintaining a $47.00 price target. Trading ...
Strong Growth Potential Could Lift These 2 AI-Related Stocks Higher, Says Stifel
The race for AI supremacy has taken an unexpected twist as Chinese AI startup DeepSeek’s latest AI model, which is both ...